By: IPP Bureau
Last updated : November 16, 2026 7:11 pm
PEBRILZO further strengthens Biocon’s oncology portfolio, now totaling five biosimilar therapies for cancer in the United States
Global biopharmaceutical company Biocon Limited announced today that the U.S. Food and Drug Administration (FDA) has approved Pebrilzo (pertuzumab-qcay). As a biosimilar to Perjeta (pertuzumab), this monoclonal antibody treats HER2-positive breast cancer by blocking HER2 receptors on cancer cells. This milestone expands Biocon’s growing oncology portfolio.
Shreehas Tambe, CEO & Managing Director, Biocon Limited, said, “The U.S. FDA approval of PEBRILZO, our biosimilar pertuzumab, marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars. For patients diagnosed with HER2-positive breast cancer, the burden of the disease extends well beyond the physical challenges, often placing considerable financial strain on patients and their families. As our fifth oncology biosimilar to receive U.S. FDA approval, PEBRILZO strengthens our anti-cancer portfolio and advances our commitment to expanding access to high-quality, affordable biologic medicines.”
In September 2026, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended marketing authorization for Biocon’s Pebrilzo (pertuzumab), a 420 mg concentrate solution for infusion, to treat HER2-positive breast cancer across multiple stages in Europe.
Biocon also announced a global settlement and license agreement with Genentech securing the earliest licensed launch date for PEBRILZO in the United States in Q3 of calendar year 2028.
Biocon’s oncology strategy combines an established portfolio with continued development across additional treatment approaches. PEBRILZO will join its robust portfolio of oncology therapies, which includes Ogivri (trastuzumab-dkst), Jobevne (bevacizumab-nwgd), Fulphila (pegfilgrastim-jmdb), and Aukelso (denosumab-kyqq). Building on this foundation, Biocon’s growing oncology pipeline includes proposed biosimilars to trastuzumab/hyaluronidase, nivolumab and pembrolizumab, spanning HER2-directed therapy and immuno-oncology.